Halog Generic Name & Formulations
Halcinonide 0.1%; crm, oint.
Crm, oint—30g, 60g, 240g
Halog Dosage and Administration
Adults and Children
Apply to affected areas 2–3 times daily. Discontinue when control is achieved. Do not occlude.
Halog Boxed Warnings
Not for oral, ophthalmic, or intravaginal use. Avoid use on face, axilla, or groin. Do not use on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Treat infection if present; discontinue if infection persists or worsens. Avoid abrupt cessation in chronic use. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Halog Adverse Reactions
Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infection, skin atrophy, striae, miliaria; HPA axis suppression (esp. in children); rare: Cushing's syndrome, hyperglycemia, glucosuria.
Halog Clinical Trials
Halog Patient Counseling